# Infliximab to Improve Retention of the Boston Keratoprosthesis in Patients After Stevens Johnson Syndrome/ Toxic Epidermal Necrolysis (SJS/TENS)

> **NCT01256489** · PHASE1,PHASE2 · WITHDRAWN · sponsor: **Massachusetts Eye and Ear Infirmary**

## Conditions studied

- Stevens-Johnson Syndrome
- Corneal Blindness

## Interventions

- **DRUG:** Infliximab

## Key facts

- **NCT ID:** NCT01256489
- **Lead sponsor:** Massachusetts Eye and Ear Infirmary
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** WITHDRAWN
- **Start date:** 2010-12
- **Primary completion:** 2015-01
- **Final completion:** 2015-01
- **Target enrollment:** 0 (ACTUAL)
- **Why stopped:** Steven Johnson's Syndrome (SJS) and Toxic Epidermal Necrolysis Syndrome (TENS) are rare (\~3 in 1 million). No eligible subjects have been identified.
- **Last updated:** 2015-11-04


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01256489

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01256489, "Infliximab to Improve Retention of the Boston Keratoprosthesis in Patients After Stevens Johnson Syndrome/ Toxic Epidermal Necrolysis (SJS/TENS)". Retrieved via AI Analytics 2026-06-14 from https://api.ai-analytics.org/clinical/NCT01256489. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*